RESUMEN
B cell depletion by the anti-CD20 antibody ocrelizumab is effective in relapsing-remitting (RR) and primary progressive (PP) multiple sclerosis (MS). We investigated immunological changes in peripheral blood of a real-world MS cohort after 6 and 12 months of ocrelizumab. All RRMS and most PPMS patients (15/20) showed treatment response. Ocrelizumab not only reduced CD20+ B cells, but also numbers of CD20+ T cells. Absolute numbers of monocytes, dendritic cells and CD8+ T cells were increased, while CD56hi natural killer cells were reduced after ocrelizumab. The residual B cell population shifted towards transitional and activated, IgA+ switched memory B cells, double negative B cells, and antibody-secreting cells. Delaying the treatment interval by 2-3 months increased mean B cell frequencies and enhanced naive B cell repopulation. Ocrelizumab reduced plasma levels of interleukin(IL)-12p70 and interferon(IFN)-α2. These findings will contribute to understanding ineffective treatment responses, dealing with life-threatening infections and further unravelling MS pathogenesis.
Asunto(s)
Anticuerpos Monoclonales Humanizados , Esclerosis Múltiple Recurrente-Remitente , Esclerosis Múltiple , Humanos , Esclerosis Múltiple/tratamiento farmacológico , Esclerosis Múltiple Recurrente-Remitente/tratamiento farmacológico , Linfocitos T CD8-positivos , Factores Inmunológicos/uso terapéutico , Interleucina-12 , Sistema InmunológicoRESUMEN
Olive oil contains several phenolic compounds with antioxidant activity, whose levels depend strongly on the kind of cultivar grown, fruit ripening effects and the oil extraction process. Therefore, the beneficial effects exerted by olive oil consumption on the resistance of low density lipoproteins (LDLs) to oxidation depend not only on an increased intake of mono-unsaturated fatty acids (e.g. oleate) which are less prone to oxidation, but also phenolic antioxidants. The aim of this study was to analyze in vitro effects exerted on the oxidative modification of Cu-stimulated human LDL by two olive oil biophenols, i.e. 3,4-dihydroxyphenylethanol-elenolic acid (3,4-DHPEA-EA) and protocatecuic acid. These compounds have not been investigated in as much detail as the better-known olive oil biophenols - such as tyrosol (p-HPEA), o-coumaric acid, vanillic acid, caffeic acid, oleuropein and 3,4-dihydroxyphenylethanol (3,4-DHPEA). Modification of LDL was tested by measuring the formation of intermediate and end products of lipid peroxidation such as conjugated dienes, lipid hydroperoxides, cholesterol and cholesteryl ester oxides, as well as studying the decrease in oxidizable substrates like polyunsaturated fatty acids. In addition, the increase in LDL negative charges was evaluated. The results demonstrate the two-tested olive oil biophenols show high antioxidant activities. In particular, protocatecuic acid and 3,4-DHPEA-EA show an antioxidant activity comparable with that of caffeic acid, oleuropein and 3,4-DHPEA. They are not only able to retard lipid peroxidation, but also to reduce the extent of its activity.
Asunto(s)
Antioxidantes/farmacología , Hidroxibenzoatos/farmacología , Peróxidos Lipídicos/análisis , Lipoproteínas LDL/sangre , Fenoles/farmacología , Aceites de Plantas/química , Piranos/farmacología , Antioxidantes/aislamiento & purificación , Ácido Araquidónico/análisis , Colesterol/análisis , Ácidos Grasos/análisis , Humanos , Hidroxibenzoatos/aislamiento & purificación , Ácido Linoleico/análisis , Lipoproteínas LDL/efectos de los fármacos , Lipoproteínas LDL/aislamiento & purificación , Aceite de Oliva , Fenoles/aislamiento & purificación , Aceites de Plantas/farmacología , Piranos/aislamiento & purificaciónRESUMEN
We investigated whether S-adenosyl-L-methionine (SAMe), dilinoleoylphosphatidylcholine (DLPC), or SAMe + DLPC influence liver lipid composition as well as acute ethanol hepatotoxicity in the isolated perfused rat liver (IPRL). SAMe (25 mg/kg intramuscularly three times a day) was administered for five consecutive days, while DLPC was administered intraperitoneally for five days. The liver was then isolated, perfused with taurocholate to stabilize bile secretion, and exposed to 0.5% ethanol for 70 min. SAMe, without changing total phospholipid (PL) content, induced an increase in the phosphatidylcholine/phosphatidylethanolamine (PC/PE) molar ratio in both liver homogenate and microsomes and a significant enrichment of 16:0-20:4 and 18:0-20:4 PC molecular species. DLPC induced a significant enrichment of PL in liver homogenate and microsomes due to a contemporary increase in PC and PE. The PC enrichment specifically involved 16:0-20:4 and 18:0-20:4 PC molecular species besides the HPLC peak containing the administered 18:2-18:2 PC species. DLPC + SAMe increased the concentration of PC in liver homogenate and microsomes due to a specific enrichment of 16:0-22:6, 16:0-20:4, and 18:0-20:4 PC molecular species, and the HPLC peak containing the administered 18:2-18:2 PC species. Ethanol acute exposure in the control IPRLs for 70 min induced a depletion of cholesterol in both liver homogenate and microsomes without significant changes in the composition of PL classes and PC molecular species. SAMe, DLPC, or SAMe + DLPC counteracted the cholesterol depletion induced by ethanol, indicating that phospholipid changes promoted by these treatments all induce a major resistance of liver membranes to the effect of ethanol. Ethanol administration in control IPRLs induced a fivefold increase of AST and LDH release in the perfusate, depletion of glutathione in homogenates and mitochondria, decreased oxygen liver consumption, and inhibition of bile flow. These effects of ethanol were significantly antagonized by SAMe. In contrast, DLPC alone only minimally attenuated enzyme release in the perfusate and the inhibitory effect of ethanol on bile flow, but it failed to influence the depletion of total and mitochondrial glutathione or the depressed oxygen consumption induced by ethanol. DLPC, administered together with SAMe, added nothing to the protective effect of SAMe against ethanol hepatotoxicity and cholestasis. In conclusion, this study demonstrates that both SAMe and DLPC induced marked modifications in the lipid composition of liver membranes with a similar enrichment of polyunsaturated PC molecular species. Only SAMe, however, significantly protected against the hepatotoxic and cholestatic effect of acute ethanol administration, an effect associated with maintained normal glutathione mitochondrial levels and oxygen liver consumption. This indicates that the protective effect of SAMe against ethanol toxicity is linked to multiple mechanisms, the maintenance of glutathione levels probably being one of the most important.
Asunto(s)
Etanol/toxicidad , Lípidos/análisis , Hígado/química , Hígado/efectos de los fármacos , Fosfatidilcolinas/farmacología , S-Adenosilmetionina/farmacología , Animales , Bilis/fisiología , Colesterol/análisis , Glutatión/análisis , Técnicas In Vitro , Hígado/metabolismo , Masculino , Microsomas Hepáticos/química , Consumo de Oxígeno/efectos de los fármacos , Fosfatidilcolinas/análisis , Fosfatidiletanolaminas/análisis , Fosfolípidos/análisis , Ratas , Ratas WistarRESUMEN
Between 1981 and 1991, 348 Swanson metacarpophalangeal replacements were implanted in patients with rheumatoid arthritis. There were 64 female and seven male patients. Both hands were reconstructed in 18 patients. Clinically, 170 implants were available for an average of 5.2 years (range, 2-10 years) followup. Severe synovitis was seen in 7% of metacarpophalangeal joints, moderate synovitis in 25%, slight synovitis in 17%, and synovitis was not present in 51%. Pain was found to be severe in 4% of the joints, moderate in 3%, slight in 39%, and not present in 54% of the joints. The average preoperative active arc of motion was 38 degrees, and the average postoperative arc of motion was 27 degrees. Eleven of 12 fractures found were revised. There were no infections. Functionally, of 58 patients assessed, 58 (100%) reported the ability to feed themselves, 55 (94%) to button clothes, and 54 (93%) to write. Quality radiographs were available in 144 joints. Eighty-four percent of implants showed sclerosis of bone and 8% showed resorption adjacent to the implant. Survivorship analysis revealed a 94% success rate at 5 years, 93% at 7 years, and 90% at 10 years using the end point of revision surgery.